BIO - Bio-Rad Laboratories Inc.
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
34%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -2.46%
Operating Income Growth is -22.62%
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -85.16%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 5.99
Debt Ratio is 0.3
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.13
Cash Flow is STRONG
Cash from Operations Growth is 48.66%
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Bio-Rad Laboratories Inc. (BIO) - http://www.bio-rad.com/
bio-rad laboratories (nyse: bio and biob) offers a broad range of innovative tools and services to the life science research and clinical diagnostics markets. founded in 1952, bio-rad has a global team of more than 7,600 employees and serves more than 100,000 research and industry customers worldwide through the company's global network of operations. throughout its existence, bio-rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more. based in hercules, ca, bio-rad has operations worldwide.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Norman Schwartz
Employees - 8,073
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.